ArticleUpsala journal of medical sciences2010
Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients.
Article in Upsala journal of medical sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Elevated Serum DcR3, Fas, and NLR Ratio are correlated with the progression of Liver Cirrhosis.American journal of translational research · 2025Article
- Role of TGFβ3-Smads-Sp1 axis in DcR3-mediated immune escape of hepatocellular carcinoma.Oncogenesis · 2019Article
- Clinical significance of decoy receptor 3 upregulation in patients with hepatitis B and liver fibrosis.Oncology letters · 2018Article
- Clinical significance and effect of MTDH/AEG-1 in bladder urothelial cancer: a study based on immunohistochemistry, RNA-seq, and in vitro verification.Cancer management and research · 2018Article
- DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC.Oncotarget · 2016Article
- Expression and clinicopathological implication of DcR3 in lung cancer tissues: a tissue microarray study with 365 cases.OncoTargets and therapy · 2016Article
- Elevated Serum Levels of the Antiapoptotic Protein Decoy-Receptor 3 Are Associated with Advanced Liver Disease.Canadian journal of gastroenterology & hepatology · 2016Article
- Aberrant expression of CDK5 infers poor outcomes for nasopharyngeal carcinoma patients.International journal of clinical and experimental pathology · 2015Article
- Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues.European journal of medical research · 2014Article
- DNA repair gene XRCC1 Arg194Trp polymorphism and susceptibility to hepatocellular carcinoma: A meta-analysis.Oncology letters · 2014Article
- Decoy receptor 3 (DcR3) overexpression predicts the prognosis and pN2 in pancreatic head carcinoma.World journal of surgical oncology · 2014Article
- Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues.Upsala journal of medical sciences · 2014Article
- Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells.BioMed research international · 2014Article
- Prognostic and clinicopathological differences of DcR3 in gastrointestinal cancer: evidence from meta-analysis.International journal of clinical and experimental medicine · 2014Article
- Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma.TheScientificWorldJournal · 2014Article
- Article
- The Role of Decoy Receptor DcR3 in Gastrointestinal Malignancy.Cancer diagnosis & prognosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDecoy receptor 3 (DcR3), a member of the tumor necrosis factor receptor superfamily, is amplified and over-expressed in various cancers. The objective of the present study was to investigate the concentration of DcR3 in sera of hepatocellular carcinoma (HCC) patients and its clinical significance.
methodsSerum concentrations of DcR3 were measured by enzyme-linked immunosorbent assay (ELISA) in 67 patients with HCC, 8 with liver cirrhosis, 17 with cholecystitis, and in 28 healthy individuals. Immunohistochemistry was employed to access protein expression of DcR3 in the corresponding HCC tissues.
resultsSerum concentrations of DcR3 in patients with HCC or cirrhosis were significantly higher than in healthy individuals (P < 0.01). Moreover, serum concentrations of DcR3 in HCC patients were associated with TNM stage, para-cirrhosis, capsular infiltration, and metastasis or recurrence of disease (P < 0.05). There was a positive correlation between the serum concentration of DcR3 and protein expression in HCC tissues (r = 0.472, P < 0.01).
conclusionsThe high serum concentration of DcR3 might play a certain role in pathogenesis, progress, and metastasis of HCC. Moreover, DcR3 might serve as a valuable molecular indicator in early diagnosis and contribute to predicting the clinical outcome in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.